PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...

X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

A Rockville immunotherapy company struck an $8 million deal to take back ownership of the drug candidates it’s been licensing ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

Pfizer and Intel have sent warnings to the European Chemicals Agency which is considering the move Pfizer pharmaceuticals wrote that a total ban would threaten the viability of this sector.